Impact of provincial and national implementation strategies on P2Y12 inhibitor utilization for acute coronary syndrome in the elderly: an interrupted time series analysis from 2008 to 2018.
Journal
Implementation science : IS
ISSN: 1748-5908
Titre abrégé: Implement Sci
Pays: England
ID NLM: 101258411
Informations de publication
Date de publication:
21 04 2021
21 04 2021
Historique:
received:
20
10
2020
accepted:
09
04
2021
entrez:
22
4
2021
pubmed:
23
4
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Guidelines recommend both acetylsalicylic acid and ticagrelor following acute coronary syndrome (ACS), but appropriate prescription practices lag. We analyzed the impact of government medication approval, national guideline updates, and publicly funded drug coverage plans on P2Y12 inhibitor utilization. Accessing provincial databases, we obtained data for elderly ACS patients in Ontario, Canada, between 2008 and 2018. Using interrupted-time series with descriptive statistics and segmented regression analysis, we evaluated types of P2Y12 inhibitors prescribed at discharge and changes to their utilization in patients managed with percutaneous intervention (PCI), coronary artery bypass grafting (CABG) or medically, following national antiplatelet therapy guidelines (by the Canadian Cardiovascular Society), ticagrelor's national approval by Health Canada, and ticagrelor's coverage by a publicly funded medication plan. We included 114,142 patients (49.4%-PCI; mean age 75.71±6.94 and 62.3% male and 7.7%-CABG; mean age 74.11±5.63 and 73.5% male). Among PCI patients, clopidogrel utilization declined monthly after 2010 national guidelines were published (p<0.0001) and within the first month after ticagrelor's national approval by Health Canada (p=0.03). Among PCI patients, ticagrelor utilization increased within the first month (p<0.0001) and continued increasing monthly (p<0.0001) after its coverage by a publicly funded medication plan. Among PCI patients, clopidogrel utilization declined within the first month (p=0.003) and ticagrelor utilization increased monthly (p=0.05) after 2012 CCS guidelines. Among CABG patients, ticagrelor's coverage was associated with a monthly increase in its utilization (p<0.0001). National guideline updates and drug coverage by a publicly funded medication plan significantly improved P2Y12 inhibitor utilization. Barriers to appropriate antiplatelet therapy in the surgical population must be explored.
Sections du résumé
BACKGROUND
Guidelines recommend both acetylsalicylic acid and ticagrelor following acute coronary syndrome (ACS), but appropriate prescription practices lag. We analyzed the impact of government medication approval, national guideline updates, and publicly funded drug coverage plans on P2Y12 inhibitor utilization.
METHODS
Accessing provincial databases, we obtained data for elderly ACS patients in Ontario, Canada, between 2008 and 2018. Using interrupted-time series with descriptive statistics and segmented regression analysis, we evaluated types of P2Y12 inhibitors prescribed at discharge and changes to their utilization in patients managed with percutaneous intervention (PCI), coronary artery bypass grafting (CABG) or medically, following national antiplatelet therapy guidelines (by the Canadian Cardiovascular Society), ticagrelor's national approval by Health Canada, and ticagrelor's coverage by a publicly funded medication plan.
RESULTS
We included 114,142 patients (49.4%-PCI; mean age 75.71±6.94 and 62.3% male and 7.7%-CABG; mean age 74.11±5.63 and 73.5% male). Among PCI patients, clopidogrel utilization declined monthly after 2010 national guidelines were published (p<0.0001) and within the first month after ticagrelor's national approval by Health Canada (p=0.03). Among PCI patients, ticagrelor utilization increased within the first month (p<0.0001) and continued increasing monthly (p<0.0001) after its coverage by a publicly funded medication plan. Among PCI patients, clopidogrel utilization declined within the first month (p=0.003) and ticagrelor utilization increased monthly (p=0.05) after 2012 CCS guidelines. Among CABG patients, ticagrelor's coverage was associated with a monthly increase in its utilization (p<0.0001).
CONCLUSION
National guideline updates and drug coverage by a publicly funded medication plan significantly improved P2Y12 inhibitor utilization. Barriers to appropriate antiplatelet therapy in the surgical population must be explored.
Identifiants
pubmed: 33882984
doi: 10.1186/s13012-021-01117-z
pii: 10.1186/s13012-021-01117-z
pmc: PMC8059026
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
42Références
N Engl J Med. 2001 Aug 16;345(7):494-502
pubmed: 11519503
Popul Health Metr. 2003 Dec 15;1(1):10
pubmed: 14675482
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
Circulation. 2004 Sep 7;110(10):1202-8
pubmed: 15313956
Eur J Cardiothorac Surg. 2017 Sep 1;52(3):456-461
pubmed: 28387790
JAMA. 1999 Oct 20;282(15):1458-65
pubmed: 10535437
JAMA Intern Med. 2020 Mar 1;180(3):420-428
pubmed: 31930361
BMJ. 2017 Mar 6;356:i6795
pubmed: 28264797
Interact Cardiovasc Thorac Surg. 2020 Sep 1;31(3):354-363
pubmed: 32772110
J Am Coll Cardiol. 2004 May 19;43(10):1738-42
pubmed: 15145092
Heart. 2012 Dec;98(23):1710-5
pubmed: 22942294
Int J Epidemiol. 2017 Feb 1;46(1):348-355
pubmed: 27283160
Am Heart J. 2010 Nov;160(5):958-65
pubmed: 21095286
JAMA. 2018 Apr 24;319(16):1677-1686
pubmed: 29710164
J Thorac Dis. 2018 Jul;10(Suppl 18):S2106-S2108
pubmed: 30123533
J Thorac Cardiovasc Surg. 2015 Dec;150(6):1548-54.e3
pubmed: 26395051
Circulation. 2006 Jan 31;113(4):507-16
pubmed: 16449730
Int J Cardiol. 2017 Aug 1;240:30-36
pubmed: 28476519
N Engl J Med. 2008 Oct 23;359(17):1802-10
pubmed: 18946065
Acad Pediatr. 2013 Nov-Dec;13(6 Suppl):S38-44
pubmed: 24268083
Am Heart J. 2015 Nov;170(5):903-13
pubmed: 26542498
Eur Heart J. 2018 Jan 14;39(3):213-260
pubmed: 28886622
Am Heart J. 2006 Oct;152(4):627-35
pubmed: 16996826
J Am Coll Cardiol. 2002 Mar 6;39(5):886-91
pubmed: 11869857
Eur Heart J. 2011 Dec;32(23):2999-3054
pubmed: 21873419
Can J Cardiol. 2019 Aug;35(8):1030-1038
pubmed: 31376904
Am Heart J. 2016 Nov;181:26-34
pubmed: 27823690
J Am Coll Cardiol. 2014 Dec 23;64(24):e139-e228
pubmed: 25260718
Medicine (Baltimore). 2019 Aug;98(34):e16880
pubmed: 31441862
Asian Pac Cens Forum. 1983 May;9(4):7-9
pubmed: 12339028
Int J Qual Health Care. 2012 Oct;24(5):538-46
pubmed: 22893665
Lancet. 2020 Apr 25;395(10233):1374-1381
pubmed: 32334703
TH Open. 2018 Dec 21;2(4):e437-e444
pubmed: 31249972
Am J Cardiol. 2015 Jul 1;116(1):148-54
pubmed: 25933730
J Am Coll Cardiol. 2011 Feb 8;57(6):672-84
pubmed: 21194870
Can J Cardiol. 2018 Mar;34(3):214-233
pubmed: 29475527
Can J Cardiol. 2013 Nov;29(11):1334-45
pubmed: 23978596
CMAJ. 2014 Sep 2;186(12):905-11
pubmed: 25047983
N Engl J Med. 2003 Jun 26;348(26):2635-45
pubmed: 12826639
Can J Cardiol. 2014 Dec;30(12):1725-31
pubmed: 25475475
Can J Cardiol. 2011 May-Jun;27 Suppl A:S1-59
pubmed: 21640290
J Am Coll Cardiol. 2019 Sep 10;74(10):e177-e232
pubmed: 30894318